Cardiol Therapeutics Inc
TSX:CRDL
Cardiol Therapeutics Inc
Change in Working Capital
Cardiol Therapeutics Inc
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cardiol Therapeutics Inc
TSX:CRDL
|
Change in Working Capital
-CA$1.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
|
Aurora Cannabis Inc
TSX:ACB
|
Change in Working Capital
CA$10.2m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sundial Growers Inc
NASDAQ:SNDL
|
Change in Working Capital
CA$9.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Change in Working Capital
-$8.1m
|
CAGR 3-Years
-69%
|
CAGR 5-Years
37%
|
CAGR 10-Years
-55%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Change in Working Capital
-CA$46.7m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
S
|
SugarBud Craft Growers Corp
XTSX:SUGR
|
Change in Working Capital
-CA$11.8m
|
CAGR 3-Years
30%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Cardiol Therapeutics Inc
Glance View
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory therapies for cardiovascular disease (CVD). The company is headquartered in Oakville, Ontario and currently employs 11 full-time employees. The company went IPO on 2018-12-20. The firm's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.
See Also
What is Cardiol Therapeutics Inc's Change in Working Capital?
Change in Working Capital
-1.1m
CAD
Based on the financial report for Mar 31, 2025, Cardiol Therapeutics Inc's Change in Working Capital amounts to -1.1m CAD.
What is Cardiol Therapeutics Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
-57%
You don't have any saved screeners yet